Eli Lilly and Co
Industry: Major Drugs

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaboration with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

Business Summary
Eli Lilly and Company discovers, develops, manufactures and sells pharmaceutical products. The Company also has an animal health business segment. The Company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico and 22 other countries. Eli Lilly and Company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. The Company's Neuroscience products consist of Zyprexa, Strattera, Prozac, Cymbalta, Permax, Symbyax, Sarafem and YentreveÔ. Endocrine products include Humalog, Humalog Mix 75/25, Humulin, Actos, Evista, Humatrope and Forteo. Oncology products consist of Gemzar and Alimta. Animal health products include Tylan, Rumensin, Coban, Monteban, Maxiban, Apralan, Micotil, Pulmotil, Surmax, Paylean and Optaflexx. Cardiovascular agents consist of ReoPro and Xigris. Anti-infectives include Ceclor and Vancocin HCl.

Financial Summary
Eli Lilly & Co. is engaged in the discovery, development, manufacture and sale of pharmaceutical products. For the 9 months ended 9/30/05, net sales rose 5% to $10.77B. Net income fell 29% to $1.28B. Revenues reflect the strong performances of Zyprexa, Humalog, Gemzar and Evista and the recent launches of Strattera, Cialis and Forteo. Earnings were offset by an increase in asset impairment and restructuring charges.